Dr. Perl on Survival Improvement With Gilteritinib in FLT3+ AML
Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.
Alexander E. Perl, MD, associate professor in the Division of Hematology/Oncology at the Perelman School of Medicine at the University of Pennsylvania, and member of the Abramson Cancer Center, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival (OS) in patients withFLT3-mutated acute myeloid leukemia (AML) treated with the FLT3 inhibitor gilteritinib (Xospata).
In comparison to chemotherapy, the response rates were substantially higher, or at least doubled in terms of complete response (CR), CR with hematologic recovery, and overall response. In addition, Perl notes that patients in the gilteritinib arm also had higher transplantation rates of 26% versus 15% in the chemotherapy arm. These patients also remained on treatment considerably longer.
Median OS in patients who received gilteritinib was statistically significant at 9.3 months compared to 5.6 months in the chemotherapy arm. The 1-year OS rates were doubled as well, Perl says. Overall, gilteritinib outperformed chemotherapy in all measures of response.
See more of the data from this trial here
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
